Gynecologic Oncology Update

Featuring perspectives from Dr Gottfried E Konecny and Dr Brian M Slomovitz, including the following topics:
Introduction (0:00)
Preventing Ovarian Cancer (1:04)
Endometrial Cancer (5:27)
Ovarian Cancer (25:36)
Cervical Cancer (54:04)

CME information and select publications

Featuring perspectives from Dr Rachel N Grisham, including the following topics:
Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00)
Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03)
Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on trametinib and then receives avutometinib/defactinib (16:15)
Case: A woman in her mid 60s with recurrent BRAF V600E LGSOC has concerns about side effects and receives single-agent dabrafenib (19:49)

CME information and select publications

Featuring perspectives from Dr Rachel N Grisham, including the following topics:
Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00)
A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11)
Current and future role of avutometinib with defactinib for LGSOC (19:23)
A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:
Case: A woman in her late 60s with recurrence of metastatic estrogen receptor-positive endometrial cancer enrolls in a trial of CDK4/6 inhibition with an aromatase inhibitor 1 year into maintenance dostarlimab after carboplatin/paclitaxel/dostarlimab and has no evidence of disease 3 years later (0:00)
Adding a PARP inhibitor to immunotherapy and chemotherapy: The RUBY Part 2 and DUO-E trials (10:03)

CME information and select publications

Featuring an interview with Dr Ramez Eskander, including the following topics:
Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)
Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)
Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58)
Current and investigational targets of ADCs in gynecologic cancers (17:14)
Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56)
Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36)
Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34)
Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05)
Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38)

CME information and select publications